# OnCo record cda-amc (institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/institutions/cda-amc/>
  a schema:MedicalOrganization ;
  onco:kind "institution" ;
  schema:identifier "cda-amc" ;
  schema:name "Canada's Drug Agency (CDA-AMC)"@en ;
  schema:alternateName "Canada's Drug Agency"@en, "L'Agence des médicaments du Canada"@en, "CDA-AMC"@en, "CADTH"@en, "Canadian Agency for Drugs and Technologies in Health"@en, "pan-Canadian Oncology Drug Review"@en, "pCODR"@en ;
  schema:description "The national body that reviews new drugs, including cancer drugs, for value and recommends to every province except Quebec whether, and on what conditions, the public plans should pay for them; formerly CADTH."@en ;
  schema:url <https://onco.cc/institutions/cda-amc/>, <https://www.cda-amc.ca> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.cda-amc.ca>, <https://doi.org/10.3390/curroncol29020041> ;
  onco:tag "hta-body" ;
  schema:addressCountry "CA" ;
  schema:addressLocality "Ottawa" ;
  schema:latitude "45.421"^^xsd:decimal ;
  schema:longitude "-75.69"^^xsd:decimal ;
  onco:institutions <https://onco.cc/institutions/health-canada/>, <https://onco.cc/institutions/inesss/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gotfrit-cancer-drug-access-pathway-canada-curr-oncol-2022/>, <https://onco.cc/key-papers/paper-meyers-pcodr-clinical-benefit-jama-intern-med-2021/>, <https://onco.cc/key-papers/paper-srikanthan-pcodr-time-to-funding-curr-oncol-2017/>, <https://onco.cc/key-papers/paper-andersen-conditional-approval-cancer-drugs-canada-curr-oncol-2019/>, <https://onco.cc/key-papers/paper-lau-time-limited-recommendation-ptap-curr-oncol-2025/>, <https://onco.cc/key-papers/paper-jenei-project-orbis-access-lancet-oncol-2024/> .